The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OGN | -46.36% | N/A | N/A | -67% |
| S&P | +14.5% | +93.32% | +14.09% | +61% |
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
High-yielding stocks may be tantalizing, but they often come with risks.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.59B | -0.8% |
| Gross Profit | $874.00M | -6.9% |
| Gross Margin | 54.83% | -3.6% |
| Market Cap | $2.52B | -52.7% |
| Market Cap / Employee | $0.25M | 0.0% |
| Employees | 10K | 0.0% |
| Net Income | $145.00M | -25.6% |
| EBITDA | $415.00M | -8.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $599.00M | -14.9% |
| Accounts Receivable | $1.48B | -8.2% |
| Inventory | 1.5K | 13.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.78B | 1.5% |
| Short Term Debt | $115.00M | 1177.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.46% | -3.2% |
| Return On Invested Capital | 18.05% | -7.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $181.00M | -39.7% |
| Operating Free Cash Flow | $220.00M | -33.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 3.79 | 4.48 | 5.15 | 3.60 | -32.50% |
| Price to Book | 34.20 | 7.79 | 8.13 | 4.61 | -95.82% |
| Price to Sales | 0.78 | 0.61 | 0.62 | 0.40 | -52.47% |
| Price to Tangible Book Value | -0.96 | -0.79 | -0.68 | -0.45 | -55.25% |
| Price to Free Cash Flow TTM | 11.02 | 8.30 | 8.11 | 5.87 | -38.81% |
| Enterprise Value to EBITDA | 28.22 | 32.21 | 30.06 | 26.06 | -11.46% |
| Free Cash Flow Yield | 9.1% | 12.0% | 12.3% | 17.0% | 63.42% |
| Return on Equity | 429.9% | 254.2% | 159.6% | - | |
| Total Debt | $8.75B | $9.04B | $8.96B | $8.90B | 2.77% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
